Videos

Christopher Flowers, MD, describes the management of an elderly patient with relapsed follicular lymphoma using newer novel therapy.

Alexander M. Eggermont, MD, PhD, discusses the results of the KEYNOTE 054 trial of pembrolizumab versus placebo in patients with high-risk stage III melanoma after a complete resection.

Kami Maddocks, MD, reviews the case of a 76-year-old woman with stage 4 mantle cell lymphoma and evaluates the role of BTK inhibitors in the treatment of relapsed/refractory disease.

Naveen Pemmaraju, MD, discusses the clinical implications of a retrospective analysis of 26 patients with myelofibrosis who received benefit from ruxolitinib when it was rechallenged.

Manish A. Shah, MD, discusses the design and efficacy of the DESTINY-Gastric01 trial of trastuzumab deruxtecan in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Expert perspectives on the identification and management of metastatic castrate-sensitive prostate cancer in a 67-year-old man.

Thomas Hope, MD, discusses the efficacy of the 68Ga-PSMA-11 PET for the detection of pelvic nodal metastases in patients intermediate- to high-risk prostate cancer considered for radical prostatectomy with lymph node dissection.

Prasad S. Adusumilli, MD, FACS, discusses the potential role of chimeric antigen receptor T-cell therapy as treatment of solid tumors now that they have demonstrated safety and efficacy in some Hematologic Malignancies.

Chung-Han Lee, MD, PhD, discusses the efficacy of a phase 2 study of pembrolizumab and lenvatinib in patient with metastatic clear cell renal cell carcinoma who have progressed on an immune checkpoint inhibitor.

Hun Ju Lee, MD, discusses the clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib in a phase 1b/2 study of patients with mantle cell lymphoma or chronic lymphocytic leukemia.

Courtney D. DiNardo, MD, discusses the current treatment landscape for patients with IDH1-mutated acute myeloid leukemia and how potential doublet and triplet combinations may play a role in this setting.

Michael Wang, MD, discusses the pharmacological profile of KTE-X19 in patients with high- or low-risk relapsed/refractory mantle cell lymphoma in the ZUMA-2 trial.